» Articles » PMID: 25730185

G-CSF-primed BM for Allogeneic SCT: Revisited

Overview
Specialty General Surgery
Date 2015 Mar 3
PMID 25730185
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

G-SCF-mobilized PBSC (GPB) grafts have a higher cell dose and somewhat more committed progenitor cells than steady-state BM (SBM), resulting in faster engraftment and faster immunological reconstitution. On the other hand, transplant related mortality (TRM), disease-free survival (DFS) and overall survival (OS) are similar both for PB and for BM. In contrast to SBM, G-CSF-primed BM (GBM) grafts stimulate HSC proliferation, increasing cell dose and thus resulting in faster engraftment because of higher cell dose infused, or because of treatment with G-CSF. Furthermore, GBM may induce tolerance and functional modulations in donor hematopoiesis and immunity, further reducing GVHD incidence, which is already lower with SBM compared with GPB grafts. Overall, a growing body of clinical evidence suggests that GBM transplants may share the advantages of GPB transplantations, without the associated increased risk of GVHD, and might be an attractive graft source for allogeneic SCTs.

Citing Articles

Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice.

Radtke S, Gorgens A, Vitoriano da Conceicao Castro S, Kordelas L, Koninger A, Durig J Sci Rep. 2019; 9(1):12914.

PMID: 31501490 PMC: 6733927. DOI: 10.1038/s41598-019-49221-x.


T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.

Vadakekolathu J, Rutella S Biomedicines. 2017; 5(2).

PMID: 28635677 PMC: 5489819. DOI: 10.3390/biomedicines5020033.

References
1.
Thomas E, Storb R, Clift R, Fefer A, Johnson F, Neiman P . Bone-marrow transplantation (first of two parts). N Engl J Med. 1975; 292(16):832-43. DOI: 10.1056/NEJM197504172921605. View

2.
Pessach I, Shimoni A, Nagler A . Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?. Hum Reprod Update. 2013; 19(3):259-67. DOI: 10.1093/humupd/dms053. View

3.
Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006; 38(4):291-7. DOI: 10.1038/sj.bmt.1705445. View

4.
Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 15(2):257-65. DOI: 10.1016/j.bbmt.2008.11.025. View

5.
Chang Y, Zhao X, Huo M, Huang X . Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl Immunol. 2009; 21(4):228-33. DOI: 10.1016/j.trim.2009.05.005. View